Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 9/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 9/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451879 | 0.85 | CSNK2A1 (0.45) | CSNK2A2CSNK2BTP53CSNK2A1ALDH1A1 | |
| SCHEMBL13866594 | 0.84 | CSNK2A2 (0.54) | CSNK2A2CSNK2BCSNK2A1MEN1ALDH1A1 | |
| SCHEMBL628533 | 0.84 | CSNK2A1 (0.61) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10131964 | 0.83 | CSNK2A1 (0.52) | CSNK2A1 | |
| SCHEMBL629427 | 0.83 | CSNK2A1 (0.67) | CSNK2A2CSNK2BTP53CSNK2A1MEN1 | |
| SCHEMBL1450870 | 0.82 | CSNK2A2 (0.55) | CSNK2A2CSNK2BCSNK2A1MEN1ALDH1A1 | |
| SCHEMBL1450931 | 0.80 | CSNK2A2 (0.83) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10132011 | 0.79 | CSNK2A1 (0.46) | CSNK2A2CSNK2BCSNK2A1ALDH1A1MAPT | |
| SCHEMBL4972289 | 0.78 | CSNK2A1 (0.59) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1450213 | 0.75 | CSNK2A2 (0.80) | CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910600-B2 | Therapeutic kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910600-B2 | Therapeutic kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910600-B2 | Therapeutic kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | CSNK2A2 11/4885CSNK2B 16/4885TP53 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.